The rate of diabetes among persons taking certain newer anti-psychotic medications is higher than that found in the general population, Yale researchers report in a study in the American Journal of Psychiatry. The study followed patients with schizophrenia and no history of diabetes who used four of six new atypical medications or conventional anti-psychotic medications. The atypical medications Ñ- clozapine, risperidone, olanzapine, quetiapine Ñ- are considered to cause fewer severe side effects. Two atypical medications were not included because they had just been approved at the time the study began.
